CPD 100Alternative Names: CPD-100
Latest Information Update: 01 Aug 2016
At a glance
- Originator Novacea
- Developer Cascade Prodrug
- Class Antineoplastics; Vinca alkaloids
- Mechanism of Action Mitosis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Aug 2016 Preclinical development is underway in the US